Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer



Status:Completed
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:January 2009
End Date:October 2015

Use our guide to learn which trials are right for you!

A Phase I Trial to Evaluate Cyclooxygenase 2 Inhibitor-Mediated Modulation of T Regulatory Cells in Advanced Non-Small Cell Lung Cancer (NSCLC)

RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. It may also stimulate the immune system in different ways and stop
tumor cells from growing.

PURPOSE: This phase I trial is studying the side effects and best dose of celecoxib in
treating patients with stage IIIB or stage IV non-small cell lung cancer.

OBJECTIVES:

Primary

- Determine the optimal biologic dose (OBD) of celecoxib that is necessary to decrease
peripheral blood lymphocyte CD4+ and CD25+ T-lymphocyte regulatory cells in patients
with stage IIIB or IV non-small cell lung cancer.

Secondary

- Determine the OBD of this drug that is necessary to decrease peripheral blood
lymphocyte FOXP3 levels in these patients.

OUTLINE: This is a nonrandomized, dose-escalation study.

Patients receive oral celecoxib twice daily on days 1-7 in the absence of unacceptable
toxicity.

Cohorts of 3 patients receive escalating doses of celecoxib until the optimal biologic dose
(OBD) is determined. The OBD is defined as the lowest dose that results in the maximum
decrease in peripheral blood lymphocyte CD4+ and CD25+ T-lymphocyte regulatory cells and
FOXP3 levels where no dose-limiting toxicity occurs. An additional 15 patients are treated
at the OBD.

PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.

Inclusion Criteria:

- Histologically confirmed non-small cell lung cancer

- Stage IIIB or IV disease

- Radiographically measurable disease

- 18 and over

- Performance status: ECOG 0-2

- Renal: Creatinine ≤ 2 mg/dL

- Negative pregnancy test

- Fertile patients must use effective contraception

- More than 4 weeks since prior chemotherapy

- Endocrine therapy: More than 4 weeks since prior corticosteroids; No concurrent
corticosteroids, including chronic corticosteroids, except for medically-indicated
topical steroids

- Radiotherapy: More than 4 weeks since prior radiotherapy

- More than 4 weeks since other prior anticancer therapy

- More than 4 weeks since prior non-cytotoxic investigational agents

- At least 72 hours since prior nonsteroidal anti-inflammatory drugs (NSAIDs)

Exclusion Criteria:

- pregnant or nursing

- comorbid disease, psychiatric condition, chronic medical condition, or laboratory
abnormality that would preclude study treatment or compliance with study requirements

- hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any study
reagent

- history of gastrointestinal ulceration, bleeding, or perforation

- other concurrent cyclooxygenase-2 or -3 inhibitors

- other concurrent NSAIDs
We found this trial at
1
site
10833 Le Conte Avenue # 8-950
Los Angeles, California 90095
(310) 825-5268
Jonsson Comprehensive Cancer Center at UCLA In the late 1960s, a group of scientists and...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials